These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

719 related articles for article (PubMed ID: 26526555)

  • 1. Doxorubicin-Bound Albumin Nanoparticles Containing a TRAIL Protein for Targeted Treatment of Colon Cancer.
    Thao le Q; Byeon HJ; Lee C; Lee S; Lee ES; Choi YW; Choi HG; Park ES; Lee KC; Youn YS
    Pharm Res; 2016 Mar; 33(3):615-26. PubMed ID: 26526555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhalable self-assembled albumin nanoparticles for treating drug-resistant lung cancer.
    Choi SH; Byeon HJ; Choi JS; Thao L; Kim I; Lee ES; Shin BS; Lee KC; Youn YS
    J Control Release; 2015 Jan; 197():199-207. PubMed ID: 25445703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Facile one-pot formulation of TRAIL-embedded paclitaxel-bound albumin nanoparticles for the treatment of pancreatic cancer.
    Min SY; Byeon HJ; Lee C; Seo J; Lee ES; Shin BS; Choi HG; Lee KC; Youn YS
    Int J Pharm; 2015 Oct; 494(1):506-15. PubMed ID: 26315118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types.
    Bae S; Ma K; Kim TH; Lee ES; Oh KT; Park ES; Lee KC; Youn YS
    Biomaterials; 2012 Feb; 33(5):1536-46. PubMed ID: 22118776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Doxorubicin-loaded nanoparticles consisted of cationic- and mannose-modified-albumins for dual-targeting in brain tumors.
    Byeon HJ; Thao le Q; Lee S; Min SY; Lee ES; Shin BS; Choi HG; Youn YS
    J Control Release; 2016 Mar; 225():301-13. PubMed ID: 26826308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Doxorubicin-loaded glycyrrhetinic acid modified recombinant human serum albumin nanoparticles for targeting liver tumor chemotherapy.
    Qi WW; Yu HY; Guo H; Lou J; Wang ZM; Liu P; Sapin-Minet A; Maincent P; Hong XC; Hu XM; Xiao YL
    Mol Pharm; 2015 Mar; 12(3):675-83. PubMed ID: 25584860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delivery of tumor-homing TRAIL sensitizer with long-acting TRAIL as a therapy for TRAIL-resistant tumors.
    Oh Y; Swierczewska M; Kim TH; Lim SM; Eom HN; Park JH; Na DH; Kim K; Lee KC; Pomper MG; Lee S
    J Control Release; 2015 Dec; 220(Pt B):671-81. PubMed ID: 26381901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation and characterization of water-soluble albumin-bound curcumin nanoparticles with improved antitumor activity.
    Kim TH; Jiang HH; Youn YS; Park CW; Tak KK; Lee S; Kim H; Jon S; Chen X; Lee KC
    Int J Pharm; 2011 Jan; 403(1-2):285-91. PubMed ID: 21035530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel prototype of albumin nanoparticles fabricated by supramolecular cyclodextrin-adamantane association.
    Lee S; Lee C; Kim B; Thao LQ; Lee ES; Kim JO; Oh KT; Choi HG; Youn YS
    Colloids Surf B Biointerfaces; 2016 Nov; 147():281-290. PubMed ID: 27522557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation and characterization of Apo2L/TNF-related apoptosis-inducing ligand-loaded human serum albumin nanoparticles with improved stability and tumor distribution.
    Kim TH; Jiang HH; Youn YS; Park CW; Lim SM; Jin CH; Tak KK; Lee HS; Lee KC
    J Pharm Sci; 2011 Feb; 100(2):482-91. PubMed ID: 20669330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced tumor delivery and antitumor response of doxorubicin-loaded albumin nanoparticles formulated based on a Schiff base.
    Li F; Zheng C; Xin J; Chen F; Ling H; Sun L; Webster TJ; Ming X; Liu J
    Int J Nanomedicine; 2016; 11():3875-90. PubMed ID: 27574421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.
    Zhao X; Chen Q; Li Y; Tang H; Liu W; Yang X
    Eur J Pharm Biopharm; 2015 Jun; 93():27-36. PubMed ID: 25770771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmaceutical potential of tacrolimus-loaded albumin nanoparticles having targetability to rheumatoid arthritis tissues.
    Thao le Q; Byeon HJ; Lee C; Lee S; Lee ES; Choi HG; Park ES; Youn YS
    Int J Pharm; 2016 Jan; 497(1-2):268-76. PubMed ID: 26657273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic anti-cancer effects via co-delivery of TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) and doxorubicin using micellar nanoparticles.
    Lee AL; Dhillon SH; Wang Y; Pervaiz S; Fan W; Yang YY
    Mol Biosyst; 2011 May; 7(5):1512-22. PubMed ID: 21350763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGF-modified mPEG-PLGA-PLL nanoparticle for delivering doxorubicin combined with Bcl-2 siRNA as a potential treatment strategy for lung cancer.
    Zhang X; Wang Q; Qin L; Fu H; Fang Y; Han B; Duan Y
    Drug Deliv; 2016 Oct; 23(8):2936-2945. PubMed ID: 26739487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human Serum Albumin Nanoparticles as a Novel Delivery System for Cabazitaxel.
    Zhou G; Jin X; Zhu P; Yao JU; Zhang Y; Teng L; Lee RJ; Zhang X; Hong W
    Anticancer Res; 2016 Apr; 36(4):1649-56. PubMed ID: 27069142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxorubicin and paclitaxel co-bound lactosylated albumin nanoparticles having targetability to hepatocellular carcinoma.
    Thao LQ; Lee C; Kim B; Lee S; Kim TH; Kim JO; Lee ES; Oh KT; Choi HG; Yoo SD; Youn YS
    Colloids Surf B Biointerfaces; 2017 Apr; 152():183-191. PubMed ID: 28110040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PEGylated TNF-related apoptosis-inducing ligand (TRAIL) for effective tumor combination therapy.
    Jiang HH; Kim TH; Lee S; Chen X; Youn YS; Lee KC
    Biomaterials; 2011 Nov; 32(33):8529-37. PubMed ID: 21855130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved biological half-life and anti-tumor activity of TNF-related apoptosis-inducing ligand (TRAIL) using PEG-exposed nanoparticles.
    Lim SM; Kim TH; Jiang HH; Park CW; Lee S; Chen X; Lee KC
    Biomaterials; 2011 May; 32(13):3538-46. PubMed ID: 21306770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Folate-mediated poly(3-hydroxybutyrate-co-3-hydroxyoctanoate) nanoparticles for targeting drug delivery.
    Zhang C; Zhao L; Dong Y; Zhang X; Lin J; Chen Z
    Eur J Pharm Biopharm; 2010 Sep; 76(1):10-6. PubMed ID: 20472060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.